786-O

Zellname	Beschreibung	Bestell-Nr.	Einheit	Preis, Euro
786-O	Humane Nierenkarzinom Zell-Linie	300107	cryovial	265,00
786-O	Humane Nierenkarzinom Zell-Linie	330107	vital	335,00

Designation:	786-O
Depositor:	CLS
Organism:	Homo sapiens (human)
Ethnicity:	Caucasian
Age/Stage:	58 years
Gender:	male
Tissue:	kidney
Morphology:	epithelial
Celltype:	renal cell adenocarcinoma
Growth Properties:	monolayer
Description:	This line was derived from a primary clear cell adenocarcinoma. The cells display both microvilli and desmosomes, and can be grown in soft agar. The cells produce a PTH like peptides that is identical to peptides produced by breast and lung tumors. The peptide has an N terminal sequence similar to PTH, has PTH like activity, and has a molecular weight of 6000 daltons.
Culture Medium:	RPMI 1640 medium supplemented with L-glutamine and 10% fetal bovine serum.
Subculturing:	Remove medium and rinse with 0.02% EDTA. Add fresh 0.025% trypsin/0.02% EDTA solution and let the culture sit at 37°C until the cells detach. Remove trypsin by centrifugation, add fresh medium, aspirate and dispense into new flasks.
Split Ratio:	A ratio of 1:4 to 1:12 is recommended
Fluid Renewal:	every 2 to 3 days
Freeze Medium:	CM-1 (CLS ∙ Cell Lines Service)
Sterility:	Tests for mycoplasma, bacteria and fungi were negative
Biosafety Level:	1
Tumorigenic:	yes, in immunosuppressed hamsters
Karyotype:	hypertriploid; Y was present in 60% of cells examined
DNA Profile (STR):	Amelogenin: X,Y CSF1PO: 10 D13S317: 8 D16S539: 12 D5S818: 9 D7S820: 11,12 THO1: 6,9.3 TPOX: 8,11 vWA: 15,17 D3S1358: 16 D21S11: 29,30 D18S51: 13,14 Penta E: 7,16 Penta D: 9,12 D8S1179: 13 FGA: 24,25 CLS ∙ Cell Lines Service, 2010.
Receptors Expressed:	CAIX positive (FACS analysis).
Products:	parathyroid hormone (PTH) like peptide
References: Williams RD et al. In vitro cultivation of human renal cell cancer. I. Establishment of cells in culture. In Vitro 12: 623-627, 1976. Williams RD et al. In vitro cultivation of human renal cell cancer. II. Characterization of cell lines. In Vitro 14: 779-786, 1978. Nissenson RA et al. Activation of the parathyroid hormone receptor-adenylate cyclase system in osteosarcoma cells by a human renal carcinoma factor. Cancer Res 45: 5358-63, 1985. Strewler GJ et al. Pathogenesis of hypercalcemia in nude mice bearing a human renal carcinoma. Endocrinology 119: 303-10, 1986. Thiede MA et al. Human renal carcinoma expresses two messages encoding a parathyroid hormone-like peptide: evidence for the alternative splicing of a single-copy gene. Proc Natl Acad Sci U S A 85: 4605-9, 1988. Thiede MA et al. Human renal carcinoma expresses two messages encoding a parathyroid hormone-like peptide: evidence for the alternative splicing of a single- copy gene. Proc Natl Acad Sci USA 85: 4605-4609, 1988. Kavoussi LR et al. Effect of tumor necrosis factor and interferon gamma on human renal carcinoma cell line growth. J Urol 142: 875-8, 1989. Hubbell HR et al. Differential effects of human natural interferon-alpha and mismatched double-stranded RNA against a human renal cell carcinoma xenograft. Anticancer Res 10: 795-801, 1990. Hubbell HR et al. Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA. Cancer Immunol Immunother 34: 259-64, 1992. Kadhim SA et al. G. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 57: 4803-10, 1997. Lieubeau-Teillet B et al. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 58: 4957-62, 1998. Wuonola MA et al. The primary in vitro anticancer activity of “half-mustard type” phenothiazines in NCI's revised anticancer screening paradigm. Anticancer Res 18: 337-48, 1998. Pause A et al. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 95: 993-8, 1998. Wada H et al. The von Hippel-Lindau tumor suppressor gene product promotes, but is not essential for, NEDD8 conjugation to cullin-2. J Biol Chem 274: 36025-9, 1999. Koochekpour S et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19: 5902-12, 1999. Westenfelder C and Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-57, 2000. Plonowski A et al.Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 60: 2996-3001, 2000. Hu K and Yao X. Methyl protogracillin (NSC-698792): the spectrum of cytotoxicity against 60 human cancer cell lines in the National Cancer Institute's anticancer drug screen panel. Anticancer Drugs 12: 541-7, 2001. Gunningham SP et al. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 61: 3206-11, 2001. Griffith TS et al. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell arcinoma. Cancer Res 62: 3093-9, 2002. Ibanez de Caceres I et al. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 66: 5021-8, 2006. Hines-Peralta A et al. Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 240: 82-9, 2006. Ambrose M et al. Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor. Mol Pharmacol 69: 1879-90, 2006.